On March 2, 2019, the SEC filed an emergency action charging Arbutus Biopharma Corp. ("AB-343") with violations of the antifraud provisions of the federal securities laws.  The SEC's complaint alleges that AB-343 violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, AB-343 has been approved by the FDA for use in multiple clinical trials.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges AB-343 with violations of the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's complaint charges AB-343 with violations of Section 10(b) and Rule 10b-5, and seeks disgorgement of ill-gotten gains plus prejudgment interest, penalties, and injunctive relief.  The SEC's investigation, which is continuing, has been conducted by Kelly L. Gibson, Kelly L. Gibson, Patricia Collier, and Kimberly Sofia of the SEC's Boston Regional Office.  The litigation is continuing.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.